Elevated urinary d-lactate levels in patients with diabetes and microalbuminuria

Chu Kuang Chou, Ya Ting Lee, Shih Ming Chen, Chi Wen Hsieh, Tzu Chuan Huang, Yi Chieh Li, Jen Ai Lee

研究成果: 雜誌貢獻文章

9 引文 (Scopus)

摘要

Diabetic nephropathy (DN) has become the major cause of end-stage renal disease. Early detection of disease risk, to enable intervention before advanced renal damage occurs, is an important goal. Microalbuminuria has been used to monitor renal damage in clinical settings for years. In this study, we divided patients with diabetes into different groups based on their microalbumin values to elucidate the relationship between urinary d-lactate and corresponding microalbumin values. Group DM1 comprised of patients with an albumin-to-creatinine ratio (ACR) of less than 30. μg albumin/mg creatinine (normal range); Group DM2 comprised of patients with an ACR of 30-299. μg albumin/mg creatinine (microalbuminuria); and Group DM3 comprised of patients with an ACR of ≥300. μg albumin/mg creatinine (macroalbuminuria). The urinary d-lactate concentration of patients with diabetes was determined by pre-column fluorescence derivatization with 4-nitro-7-piperazino-2,1,3-benzoxadiazole (NBD-PZ), and the accuracy (recovery) and precision (relative standard deviation; RSD) were validated. The measured values showed an accuracy that was in the acceptable range (91.59-112.96%), with an RSD in the range of 3.13-13.21%. The urinary d-lactate levels of the 3 diabetic groups (groups DM1, DM2, and DM3) were significantly higher than those of healthy subjects (78.31. ±. 22.13, 92.47. ±. 21.98, and 47.29. ±. 17.51 vs. 6.28. ±. 2.39 nmol/mg creatinine, respectively; p

原文英語
頁(從 - 到)65-70
頁數6
期刊Journal of Pharmaceutical and Biomedical Analysis
116
DOIs
出版狀態已發佈 - 一月 13 2015

指紋

Medical problems
Lactic Acid
Creatinine
Albumins
Kidney
Diabetic Nephropathies
Chronic Kidney Failure
Early Diagnosis
Healthy Volunteers
Reference Values
Fluorescence
Recovery

ASJC Scopus subject areas

  • Analytical Chemistry
  • Drug Discovery
  • Pharmaceutical Science
  • Spectroscopy
  • Clinical Biochemistry

引用此文

Elevated urinary d-lactate levels in patients with diabetes and microalbuminuria. / Chou, Chu Kuang; Lee, Ya Ting; Chen, Shih Ming; Hsieh, Chi Wen; Huang, Tzu Chuan; Li, Yi Chieh; Lee, Jen Ai.

於: Journal of Pharmaceutical and Biomedical Analysis, 卷 116, 13.01.2015, p. 65-70.

研究成果: 雜誌貢獻文章

Chou, Chu Kuang ; Lee, Ya Ting ; Chen, Shih Ming ; Hsieh, Chi Wen ; Huang, Tzu Chuan ; Li, Yi Chieh ; Lee, Jen Ai. / Elevated urinary d-lactate levels in patients with diabetes and microalbuminuria. 於: Journal of Pharmaceutical and Biomedical Analysis. 2015 ; 卷 116. 頁 65-70.
@article{8088b8b9bf2348b7ac470a7ebde13c5d,
title = "Elevated urinary d-lactate levels in patients with diabetes and microalbuminuria",
abstract = "Diabetic nephropathy (DN) has become the major cause of end-stage renal disease. Early detection of disease risk, to enable intervention before advanced renal damage occurs, is an important goal. Microalbuminuria has been used to monitor renal damage in clinical settings for years. In this study, we divided patients with diabetes into different groups based on their microalbumin values to elucidate the relationship between urinary d-lactate and corresponding microalbumin values. Group DM1 comprised of patients with an albumin-to-creatinine ratio (ACR) of less than 30. μg albumin/mg creatinine (normal range); Group DM2 comprised of patients with an ACR of 30-299. μg albumin/mg creatinine (microalbuminuria); and Group DM3 comprised of patients with an ACR of ≥300. μg albumin/mg creatinine (macroalbuminuria). The urinary d-lactate concentration of patients with diabetes was determined by pre-column fluorescence derivatization with 4-nitro-7-piperazino-2,1,3-benzoxadiazole (NBD-PZ), and the accuracy (recovery) and precision (relative standard deviation; RSD) were validated. The measured values showed an accuracy that was in the acceptable range (91.59-112.96{\%}), with an RSD in the range of 3.13-13.21{\%}. The urinary d-lactate levels of the 3 diabetic groups (groups DM1, DM2, and DM3) were significantly higher than those of healthy subjects (78.31. ±. 22.13, 92.47. ±. 21.98, and 47.29. ±. 17.51 vs. 6.28. ±. 2.39 nmol/mg creatinine, respectively; p",
keywords = "D-lactate, Diabetes, Fluorescence derivatization, Microalbumin, NBD-PZ",
author = "Chou, {Chu Kuang} and Lee, {Ya Ting} and Chen, {Shih Ming} and Hsieh, {Chi Wen} and Huang, {Tzu Chuan} and Li, {Yi Chieh} and Lee, {Jen Ai}",
year = "2015",
month = "1",
day = "13",
doi = "10.1016/j.jpba.2015.06.014",
language = "English",
volume = "116",
pages = "65--70",
journal = "Journal of Pharmaceutical and Biomedical Analysis",
issn = "0731-7085",
publisher = "Elsevier",

}

TY - JOUR

T1 - Elevated urinary d-lactate levels in patients with diabetes and microalbuminuria

AU - Chou, Chu Kuang

AU - Lee, Ya Ting

AU - Chen, Shih Ming

AU - Hsieh, Chi Wen

AU - Huang, Tzu Chuan

AU - Li, Yi Chieh

AU - Lee, Jen Ai

PY - 2015/1/13

Y1 - 2015/1/13

N2 - Diabetic nephropathy (DN) has become the major cause of end-stage renal disease. Early detection of disease risk, to enable intervention before advanced renal damage occurs, is an important goal. Microalbuminuria has been used to monitor renal damage in clinical settings for years. In this study, we divided patients with diabetes into different groups based on their microalbumin values to elucidate the relationship between urinary d-lactate and corresponding microalbumin values. Group DM1 comprised of patients with an albumin-to-creatinine ratio (ACR) of less than 30. μg albumin/mg creatinine (normal range); Group DM2 comprised of patients with an ACR of 30-299. μg albumin/mg creatinine (microalbuminuria); and Group DM3 comprised of patients with an ACR of ≥300. μg albumin/mg creatinine (macroalbuminuria). The urinary d-lactate concentration of patients with diabetes was determined by pre-column fluorescence derivatization with 4-nitro-7-piperazino-2,1,3-benzoxadiazole (NBD-PZ), and the accuracy (recovery) and precision (relative standard deviation; RSD) were validated. The measured values showed an accuracy that was in the acceptable range (91.59-112.96%), with an RSD in the range of 3.13-13.21%. The urinary d-lactate levels of the 3 diabetic groups (groups DM1, DM2, and DM3) were significantly higher than those of healthy subjects (78.31. ±. 22.13, 92.47. ±. 21.98, and 47.29. ±. 17.51 vs. 6.28. ±. 2.39 nmol/mg creatinine, respectively; p

AB - Diabetic nephropathy (DN) has become the major cause of end-stage renal disease. Early detection of disease risk, to enable intervention before advanced renal damage occurs, is an important goal. Microalbuminuria has been used to monitor renal damage in clinical settings for years. In this study, we divided patients with diabetes into different groups based on their microalbumin values to elucidate the relationship between urinary d-lactate and corresponding microalbumin values. Group DM1 comprised of patients with an albumin-to-creatinine ratio (ACR) of less than 30. μg albumin/mg creatinine (normal range); Group DM2 comprised of patients with an ACR of 30-299. μg albumin/mg creatinine (microalbuminuria); and Group DM3 comprised of patients with an ACR of ≥300. μg albumin/mg creatinine (macroalbuminuria). The urinary d-lactate concentration of patients with diabetes was determined by pre-column fluorescence derivatization with 4-nitro-7-piperazino-2,1,3-benzoxadiazole (NBD-PZ), and the accuracy (recovery) and precision (relative standard deviation; RSD) were validated. The measured values showed an accuracy that was in the acceptable range (91.59-112.96%), with an RSD in the range of 3.13-13.21%. The urinary d-lactate levels of the 3 diabetic groups (groups DM1, DM2, and DM3) were significantly higher than those of healthy subjects (78.31. ±. 22.13, 92.47. ±. 21.98, and 47.29. ±. 17.51 vs. 6.28. ±. 2.39 nmol/mg creatinine, respectively; p

KW - D-lactate

KW - Diabetes

KW - Fluorescence derivatization

KW - Microalbumin

KW - NBD-PZ

UR - http://www.scopus.com/inward/record.url?scp=84945473107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945473107&partnerID=8YFLogxK

U2 - 10.1016/j.jpba.2015.06.014

DO - 10.1016/j.jpba.2015.06.014

M3 - Article

C2 - 26166004

AN - SCOPUS:84945473107

VL - 116

SP - 65

EP - 70

JO - Journal of Pharmaceutical and Biomedical Analysis

JF - Journal of Pharmaceutical and Biomedical Analysis

SN - 0731-7085

ER -